Physician

Melvin P. Palalay, M.D.

According to 2025 Medicare claims, Melvin Palalay, M.D. (NPI: 1508833971) practices hematology/oncology in the Urban Honolulu, HI market, with the plurality of this provider's patient population coming from Honolulu, HI. This provider's primary affiliated billing organization is AMERICAN ONCOLOGY PARTNERS OF HAWAII, LLC (NPI: 1629835814; TIN: 991656366) and primary practice location at 96813-4929. Palalay is affiliated with the QCIPN (ACO ID: A4614), participating under the MSSP model.

Palalay's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 593 traditional Medicare patients, billed 75,533 HCPCS/CPT codes, and received $1,473,787 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,760 prescription claims across 302 beneficiaries totaling $7,629,236 in drug costs, led by Keytruda (Pembrolizumab). DME data shows 22 claims. Open Payments data shows 155 records totaling $3,895. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $533,579 and ending at $1,473,787. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,321,207 to $7,629,236. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	303	46,548	$533,579
2016	334	54,202	$638,613
2017	384	79,992	$810,395
2018	351	63,850	$691,719
2019	363	63,686	$935,413
2020	358	107,267	$1,575,134
2021	506	118,877	$2,135,487
2022	541	83,271	$1,330,667
2023	562	18,526	$360,597
2024	593	75,533	$1,473,787

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	218	1,500	$1,321,207
2016	204	1,230	$1,846,936
2017	234	1,330	$1,802,804
2018	244	1,591	$2,864,185
2019	267	1,776	$4,344,028
2020	276	1,784	$4,859,976
2021	347	1,857	$6,276,839
2022	327	1,890	$6,331,230
2023	336	1,948	$8,134,001
2024	302	1,760	$7,629,236

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	44	$28,937
2016	N/R	81	$32,312
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	12	$2,330
2024	N/R	22	$1,033

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	427	1,288	$96
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	235	364	$69
80048	Blood test, basic group of blood chemicals (calcium, total)	233	491	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	353	1,146	$7
36415	Insertion of needle into vein for collection of blood sample	365	1,158	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Keytruda	Pembrolizumab	57	1,554	$822,571
Opdualag	Nivolumab-Relatlimab-Rmbw	16	448	$456,929
Imbruvica	Ibrutinib	24	672	$384,503
Tagrisso	Osimertinib Mesylate	19	570	$343,123
Darzalex Faspro	Daratumumab-Hyaluronidase-Fihj	24	672	$331,167

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	11	$849
E0431	Portable gaseous oxygen system, rental; includes portable container, regulator, flowmeter, humidifier, cannula or mask, and tubing	Y	N/R	11	$184

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	155	$3,895	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Melvin P. Palalay, M.D.?

Tedicare shows public-source Medicare data for Melvin P. Palalay, M.D. (NPI 1508833971), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Melvin P. Palalay, M.D. have ACO affiliation data?

Melvin P. Palalay, M.D. is shown with ACO affiliation data for QCIPN (MSSP, ACO ID A4614).

What billing organization is linked to Melvin P. Palalay, M.D.?

Melvin P. Palalay, M.D. is linked to AMERICAN ONCOLOGY PARTNERS OF HAWAII, LLC (billing NPI 1629835814) in the available physician profile data.

Does Melvin P. Palalay, M.D. have Open Payments data?

Melvin P. Palalay, M.D. has 155 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.